ABL202: A Novel Antibody-Drug Conjugate Targeting ROR1-Expressing Tumors

Time: 1:30 pm

Details:

• Examine ROR1; An attracting cancer target that expresses in various cancer including CLL, TNBC, and lung cancer
• Assess the activity of anti-ROR1 ADC that was tested on various xenograft models
• Some preclinical results will be presented for further discussion